Services Advertising. Novo Nordisk India and Torrent Pharma expand their insulin manufacturing facility. Shramana Ganguly. Rate Story. Font Size Abc Small. Abc Medium. Abc Large. Agencies Both the companies announced expansion of their insulin manufacturing facility.
Novo Nordisk India and Torrent Pharmaceuticals. Strategy As Amazon to Tesla fight for chips, global semiconductor industry change complexion amid shortage. Subscribe to ETPrime. Read before you invest. Insights on Torrent Pharmaceuticals Ltd. Project Type Insulin and parenteral facility. Owners Torrent Pharmaceuticals and Novo Nordisk. Credit: Novo Nordisk. The facility will allow Novo Nordisk India to meet growing demand in India for its insulin products.
Credit: Melissa Johnson. Novo Nordisk has been involved in developing diabetes treatments for more than 90 years. Pharmaceutical Technology Daily Update The top stories of the day delivered to you every weekday. Leading diabetes care pharmaceutical company Novo Nordisk in partnership with Torrent Pharma on Monday inaugurated an enhanced facility in Gujarat and looking at launching more new products in India. India has 73 million patients suffering from diabetes and Novo Nordisk claims it holds 60 per cent marketshare of the Rs 2, crore insulin market in the country.
Through this partnership, they aim to ensure the provision of cost-effective, high quality medication, he said. Through its manufacturing partner Torrent Pharma, the company also plans to bring more insulin products in the Indian market. He said the company is committed to address the issue by working with likeminded stakeholders to change diabetes, Kier said. Novo Nordisk claims it holds 60 per cent marketshare of the Rs 2, crore insulin market in the country.
0コメント